Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590310 | 0.94 | ALDH1A1 (0.38) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL12891024 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL12891026 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL28283697 | 0.80 | ATM (0.40) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL14509655 | 0.80 | HTT (0.35) | — | |
| SCHEMBL12156688 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL14922679 | 0.80 | ATM (0.40) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL6428879 | 0.77 | POLB (0.40) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL6948011 | 0.77 | POLB (0.40) | POLBL3MBTL1SPHK2SPHK1ALDH1A1 | |
| SCHEMBL22083386 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | POLB 3001/4885L3MBTL1 678/4885SPHK2 992/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | POLB 3001/4885L3MBTL1 678/4885SPHK2 992/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | POLB 3001/4885L3MBTL1 678/4885SPHK2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.